Centessa Pharmaceuticals

Historical price data

Centessa Pharmaceuticals, founded in 2020, consolidates specialized biotech assets under a unified, capital-efficient corporate structure with a patient-centric mission. Its primary achievement is advancing a pipeline of oral OX2R agonists, led by ORX750, which is in Phase 2 studies for narcolepsy and idiopathic hypersomnia, targeting a fundamental biological pathway for wakefulness. The company's strategy employs focused, data-driven development teams for each asset to rapidly progress programs, supported by a leadership team with deep industry and scientific expertise. A significant recent development is the announced acquisition by Eli Lilly, validating the platform's potential.

Two core platforms: 1) Orexin Receptor 2 (OX2R) Agonist platform for oral therapies in sleep-wake and neurological disorders, and 2) LockBody® bispecific antibody platform for conditionally activated immuno-oncology treatments.

Competition in the selective OX2R agonist space is limited, with Centessa's ORX750 among the most advanced. The acquisition by Eli Lilly positions the asset against symptomatic treatments from companies like Jazz Pharmaceuticals and Axsome Therapeutics, but with a potentially superior, disease-modifying mechanism. In broader neuropsychiatry, it will compete with major pharma's cognitive enhancer pipelines.